After Long Wait, Aβ Oligomer Detangler Is Poised for Phase 2
Alzforum,
10 Nov 2023 While the trials, tribulations, and successes of Aβ immunotherapy were commanding Alzheimerologists' rapt attention…
10 Nov 2023 While the trials, tribulations, and successes of Aβ immunotherapy were commanding Alzheimerologists' rapt attention…
20 May 2022 In the brains of people with Alzheimer’s disease, toxic oligomers and protofibrils of Aβ are thought to spark a…
Scientists from Germany's Jülich Research Centre are reporting successful results from the first phase of human clinical…
The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical…
Der im Forschungszentrum Jülich entwickelte Alzheimer-Wirkstoff-Kandidat PRI-002 hat die Phase I der klinischen Forschung in…
Scientists from Germany's Jülich Research Centre are reporting successful results from the first phase of human clinical…
The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical…
"In summer 2018, the drug candidate PRI-002 already proved its safety and tolerability profile in humans when administered as a…
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers.
The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical…
09:39 Der im Forschungszentrum Jülich entwickelte Alzheimer-Wirkstoff-Kandidat PRI-002 hat die Phase I der klinischen Forschung…
09:43 The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical…
"In summer 2018, the drug candidate PRI-002 already proved its safety and tolerability profile in humans when administered as a…
Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold…